168 related articles for article (PubMed ID: 35456621)
1. Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity.
Khoury A; Sakoff JA; Gilbert J; Scott KF; Karan S; Gordon CP; Aldrich-Wright JR
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456621
[TBL] [Abstract][Full Text] [Related]
2. Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells.
Khoury A; Sakoff JA; Gilbert J; Karan S; Gordon CP; Aldrich-Wright JR
Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559273
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, characterisation and influence of lipophilicity on cellular accumulation and cytotoxicity of unconventional platinum(iv) prodrugs as potent anticancer agents.
Deo KM; Sakoff J; Gilbert J; Zhang Y; Aldrich Wright JR
Dalton Trans; 2019 Nov; 48(46):17228-17240. PubMed ID: 31728483
[TBL] [Abstract][Full Text] [Related]
4. Potent Chlorambucil-Platinum(IV) Prodrugs.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142383
[TBL] [Abstract][Full Text] [Related]
5. Platinum(IV) Derivatives of [Pt(1
Kostrhunova H; McGhie BS; Markova L; Novakova O; Kasparkova J; Aldrich-Wright JR; Brabec V
J Med Chem; 2023 Jun; 66(12):7894-7908. PubMed ID: 37285472
[TBL] [Abstract][Full Text] [Related]
6. Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173934
[TBL] [Abstract][Full Text] [Related]
7. Bioactive Platinum(IV) Complexes Incorporating Halogenated Phenylacetates.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296713
[TBL] [Abstract][Full Text] [Related]
8. Multi-action platinum(IV) prodrugs conjugated with COX-inhibiting NSAIDs.
Liu X; Wenisch D; Dahlke P; Jordan PM; Jakupec MA; Kowol CR; Liebing P; Werz O; Keppler BK; Weigand W
Eur J Med Chem; 2023 Sep; 257():115515. PubMed ID: 37295160
[TBL] [Abstract][Full Text] [Related]
9. Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396859
[TBL] [Abstract][Full Text] [Related]
10. Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance.
Petruzzella E; Sirota R; Solazzo I; Gandin V; Gibson D
Chem Sci; 2018 May; 9(18):4299-4307. PubMed ID: 29780561
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterisation and potent cytotoxicity of unconventional platinum(iv) complexes with modified lipophilicity.
Deo KM; Sakoff J; Gilbert J; Zhang Y; Aldrich Wright JR
Dalton Trans; 2019 Nov; 48(46):17217-17227. PubMed ID: 31729519
[TBL] [Abstract][Full Text] [Related]
12. Does cytotoxicity of metallointercalators correlate with cellular uptake or DNA affinity?
Davis KJ; Carrall JA; Lai B; Aldrich-Wright JR; Ralph SF; Dillon CT
Dalton Trans; 2012 Aug; 41(31):9417-26. PubMed ID: 22740039
[TBL] [Abstract][Full Text] [Related]
13. Platinum(IV)-Loaded Degraded Glycol Chitosan as Efficient Platinum(IV) Drug Delivery Platform.
Lerchbammer-Kreith Y; Sommerfeld NS; Cseh K; Weng-Jiang X; Odunze U; Schätzlein AG; Uchegbu IF; Galanski MS; Jakupec MA; Keppler BK
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111536
[TBL] [Abstract][Full Text] [Related]
14. Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator.
Wang S; Higgins VJ; Aldrich-Wright JR; Wu MJ
J Chem Biol; 2012 Apr; 5(2):51-61. PubMed ID: 23226166
[TBL] [Abstract][Full Text] [Related]
15. The in vitro renal cell toxicity of some unconventional anticancer phenanthroline-based platinum(II) complexes.
Ng NS; Wu MJ; Myers SJ; Aldrich-Wright JR
J Inorg Biochem; 2018 Feb; 179():97-106. PubMed ID: 29197671
[TBL] [Abstract][Full Text] [Related]
16. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
Ratzon E; Najajreh Y; Salem R; Khamaisie H; Ruthardt M; Mahajna J
BMC Cancer; 2016 Feb; 16():140. PubMed ID: 26906901
[TBL] [Abstract][Full Text] [Related]
17. Pyrenebutyrate Pt(IV) Complexes with Nanomolar Anticancer Activity.
Ahmedova A; Mihaylova R; Stoykova S; Mihaylova V; Burdzhiev N; Elincheva V; Momekov G; Momekova D
Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765279
[TBL] [Abstract][Full Text] [Related]
18. Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.
Neumann W; Crews BC; Sárosi MB; Daniel CM; Ghebreselasie K; Scholz MS; Marnett LJ; Hey-Hawkins E
ChemMedChem; 2015 Jan; 10(1):183-92. PubMed ID: 25318459
[TBL] [Abstract][Full Text] [Related]
19. Cellular accumulation, lipophilicity and photocytotoxicity of diazido platinum(IV) anticancer complexes.
Pizarro AM; McQuitty RJ; Mackay FS; Zhao Y; Woods JA; Sadler PJ
ChemMedChem; 2014 Jun; 9(6):1169-75. PubMed ID: 24840112
[TBL] [Abstract][Full Text] [Related]
20. Multifaceted Studies of the DNA Interactions and In Vitro Cytotoxicity of Anticancer Polyaromatic Platinum(II) Complexes.
Pages BJ; Sakoff J; Gilbert J; Rodger A; Chmel NP; Jones NC; Kelly SM; Ang DL; Aldrich-Wright JR
Chemistry; 2016 Jun; 22(26):8943-54. PubMed ID: 27219069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
